AZTR Stock Catalyst: Azitra Inc. Reported Safety Data from Phase 1b Trial of ATR12-351 for Netherton Syndrome

Jun 16, 2025 · 6:16pm ET

The company shared results from the clinical study.

Max move

+72.4%

High of day $3.05

Sparker timei

6:16pm ET

AZTR · Jun 16, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Azitra Inc. (XASE: AZTR) announced safety data from a Phase 1b trial evaluating ATR12-351 for the treatment of Netherton Syndrome. The trial aimed to assess the safety and tolerability of the product candidate in patients with this rare genetic disorder.

The company reported the safety data without disclosing specific figures or adverse event details. No comparator data was provided for this announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time AZTR sparks.

Download Sniper App →

Catch the next AZTR-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →